The radiopharmaceuticals CDMO will have a majority stake in Agilera Pharma, advancing its strategy of becoming a fully-integrated service provider in the radiopharmaceutical therapy sector.

Drug delivery companies — SHL Medical and Kindeva Drug Delivery — have formed a partnership to enhance SHL Medical’s Molly® autoinjector platform aimed at pharmaceutical and biotechnology companies.

Advanced therapy medicinal products specialist CDMO, Porton Advanced, and clinical-stage biotech, Eureka Therapeutics, have entered a strategic collaboration to accelerate the development and commercialization of T-cell therapies for cancer treatment.

Curium, a global leader in nuclear medicine, has announced the acquisition of radiopharmaceutical company, Monrol, as the company aims to improve its position in the global nuclear medicine market,.

Novo Nordisk has entered into an exclusive global licensing agreement with Lexicon Pharmaceuticals for Lexicon’s promising drug candidate, LX9851, which targets gastrointestinal disorders.

US CDMO, Bionova Scientific, has selected New York CRO, Bionique Testing Laboratories, as its preferred provider for mycoplasma testing services in biologics manufacturing. The appointment will allow enhanced quality control processes for biologics production, ensuring the safety and efficacy of therapeutic products.

Minneapolis-based drug development company, Humanetics Corporation, with funding support from the U.S. Department of Defense, has engaged Lifecore Biomedical to provide CDMO services for BIO 300, a novel radioprotective agent aimed at preventing acute radiation syndrome.

Korean CDMO, ENCell, has signed a Memorandum of Understanding (MOU) with Japan's Cell Resources Corporation (CRC) to expand its presence in the Japanese cell and gene therapy market.

Full-service CDMO, CordenPharma, and clinical-stage biopharmaceutical company, Viking Therapeutics, have entered a multi-year strategic partnership to support the development and commercialization of Viking's GLP-1 drug candidate, VK2735.

Synthetic biology company, Asimov, and Korean manufacturer, Lotte Biologics, have formed a partnership to streamline the transition from cell line development to large-scale GMP production. This collaboration integrates Asimov's CHO Edge platform - known for generating high-titer, stable cell lines - with Lotte Biologics' extensive manufacturing capabilities.

Summit Therapeutics has announced a clinical trial collaboration with Pfizer to assess a novel investigational PD-1/VEGF bispecific antibody, ivonescimab, in combination with Pfizer's antibody-drug conjugates across various solid tumor settings.

Immunomodulation therapy company, Tiziana Life Sciences, has entered into a product development services agreement with Renaissance Lakewood LLC, a leading CDMO focused on nasal drug delivery, to optimize the formulation and scale-up production of Tiziana's intranasal lead candidate, foralumab, which is under development for treating neurodegenerative and inflammatory diseases or conditions.

Molecular glue company, Magnet Biomedicine has entered into a collaboration and license agreement with Eli Lilly to discover, develop, and commercialize molecular glue therapeutics, with a focus on oncology applications.

Indian pharmaceutical manufacturing company, Granules India, has acquired Swiss CDMO Senn Chemicals AG for USD 22.3 mn to expand into the peptide therapeutics market. Senn Chemicals, which specializes in liquid- and solid-phase peptide synthesis, will strengthen Granules’ position in high-growth areas like GLP-1 receptor agonists used for diabetes and obesity treatments.

Thermo Fisher Scientific has agreed to acquire Solventum's purification & filtration business for USD 4.1 bn in cash. The purification & filtration unit - which generated around USD 1 bn in revenue in 2024 - specializes in purification filters and membranes used in biopharma, medical technology, microelectronics, food and beverage production, and water filtration.

hVIVO plc., a CRO specializing in human challenge trials, announced it has signed a USD 2.5 mn contract to advance a new biopharmaceutical client’s research in human metapneumovirus (hMPV). Should the current phase of research be deemed a success, and subject to regulatory approval, the final phase of the study is expected to commence in the second half of 2025.

Novartis announced an agreement to acquire Anthos, a clinical-stage biopharmaceutical company that is developing abelacimab, a promising anticoagulant for stroke prevention in atrial fibrillation patients. Novartis will make an upfront payment of USD 925 million with potential additional payments of up to USD 2.15 billion upon achievement of specified regulatory and sales milestones.

German biopharma, Eleva, and global CDMO, 3PBIOVIAN, have announced a strategic partnership to secure production capacity at 3PBIOVIAN for the clinical-grade material needed to advance its current pipeline programs (Factor H (CPV-104) for C3G and dry AMD) into mid- to late-stage clinical development.

South Korean biopharma, Inventage Lab, is investing USD 17 mn in South Korean vaccine developer, Quratis, to secure a 40% stake and management rights in the company and strengthen its own long-acting injectable (LAI) drug platform and lipid nanoparticle (LNP) technology for mRNA vaccines and gene therapies.

Catalent, the global CDMO now in the ownership of Novo Holdings, has partnered with Belgian biotech, Galapagos NV, to expand decentralized manufacturing for GLPG5101 - an investigational CAR-T therapy for relapsed or refractory non-Hodgkin lymphoma (NHL). Catalent will support Galapagos’ upcoming clinical trials in the New Jersey and New York regions by leveraging its cell therapy facility located in Princeton, New Jersey.